This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
What are the key current challenges in the development of pain medicines? What is the present clinical landscape for pain management medicines, especially chronic pain? Pain management therapies: Pfizer’s migraine medicine recommended by NICE What are three current development trends for pain management treatments?
A paper published by the Drug Safety Research Unit (DSRU) in the British Journal for Clinical Pharmacology , has asserted the need for ongoing assessment of the safety and effectiveness of the Alzheimers drug lecanemab in the real-world clinical setting.
The Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA), Dame June Raine, will step down in the Autumn following five years in the role. Her previous role in the agency was as Director of Vigilance and Risk Management of Medicines.
Positive recommendation of talazoparib “is an important advance in expanding treatment options for eligible patients who currently have limited alternative treatments,” Chris Twelves, Director of NIHR Leeds Clinical Research Facility and Professor of Clinical Cancer Pharmacology and Oncology noted.
Victoza, Copaxone, Lupron, Zoladex, Sandostatin, and Somatuline are some of the popularly marketed peptide API therapeutic drugs while more than 600 peptide-based pharmacologicalleads are being investigated worldwide, across various phases of development. Discover the top API protein and peptide companies in contract marketing.
Several tetrapeptides are pharmacologically active, showing affinity and specificity for multiple receptors in protein-protein signalling. Amgen develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases.
Pyridine derivatives contain one nitrogen atom in a six-membered aromatic ring and are the most extensively used heterocycles in the field of drug design, due to their promising effect on pharmacological activity, which has led to the discovery of numerous broad-spectrum therapeutic agents.
As molecular targeting peptides, anti-cancer peptides penetrate the plasma membrane, nuclear membrane, and mitochondrial membrane of cancer cells, exerting pharmacological activity through various mechanisms (such as inhibiting DNA synthesis and cell division), thus causing apoptosis of cancer cells.
Cardiovascular diseases are the leading cause of death globally with over 18.5 Cardiovascular diseases are the leading cause of death globally with over 18.5 Meta‑analyses of these trials have shown that the therapy is safe and can lead to a reduction in incidences of death and recurrent myocardial infarction. to 1 percent).
A 2022 study from the Royal College of Physicians and British Pharmacological Society demonstrated the potential of pharmacogenomics, with scientists identifying the genetic cause behind an individual’s drug response for over forty medicines. Just one mutation can lead to a complete change in protein formation.
HIV treatment and prevention are at an inflection point after years of continuously improving the standard of care of once-daily oral medicines. Our industry is on the cusp of the next wave of medicines that will guide the coming decade of HIV care, making HIV a smaller part of people’s lives. 3 But that paradigm is rapidly changing.
Across swathes of primary care, pharmacological innovation has stalled; the last new antihypertensive class was introduced in 2007 and new antibiotics have trickled in at a dangerously slow pace. And all are predominantly prevented or treated with medicines that are decades old.
Personalized Medicine AI can help develop precision medicine by analyzing patient data , including demographic, clinical, and genetic information, as well as information about their metabolism and microbes, environmental exposures, and lifestyle factors, to predict how different patients will respond to various therapies.
Cala , the bioelectronic medicine leader setting a new standard of care for chronic disease, today announced the commercial launch of its next generation system: the Cala kIQ System, the first and only FDA-cleared wearable device that delivers effective therapy for action hand tremor relief in people with essential tremor and Parkinson’s disease.
Abliva is a clinical-stage company developing medicines to treat rare and severe primary mitochondrial diseases. NV354 has indicated to be safe and efficacious in pre-clinical models, with regard to optimal pharmacological properties, including high levels of brain penetration.
Investigating the next generation of genetic medicine through RNA based therapies. RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious, and chronic diseases. Heads of Translational Medicine. Website: [link].
Blank acknowledged that in many cases, an exclusively paediatric patient population could lead to difficulties with drawing consent for early phase trials. Still, Blank suggested that companies enroll the patient population that is most likely to benefit, because early phase studies contain the most safety risks.
Therapeutic drug monitoring is used to obtain peak and trough levels to determine drug serum concentration which tells us if a drug is efficacious or is leading to toxic levels. In personalized medicine, genetic information is used to tailor treatment regimens. warfarin) which leads to higher plasma concentrations. metformin).
3D medical animation for healthcare breaks out these concepts into visually digestible bits whether you’re a surgeon outlining a difficult operation or a pharmaceutical company showing how a medicine operates at the cellular level. Check out some of our resources and patient-focused medical animations.
This progress underscores the potential of gene therapy to revolutionise medicine by addressing the root causes of genetic disorders. Roger ‘s work has involved leading the strategy and build of UCB’s global gene therapy research platform and digital transformation in global research.
Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5
Research demonstrates that the greenest inhaler is the one that is used and that leads to disease control. We have programmes that investigate the types of medicines we produce and how we produce them, the energy we use (globally, 99 percent of our energy comes from renewable sources), and the practices of our entire global value chain.
The potential to target more than one tumour antigen is interesting, as are the possible advantages for the patients receiving these investigational medicines. She leads Ipsen’s Early Development Portfolio across the company’s three therapeutic focus areas (Oncology, Rare Disease and Neuroscience).
Key considerations in the candidate selection stage The first step in a drug development program is choosing the optimum molecule from a range of potential leads that have been optimized within drug discovery. We start by using in-silico modeling of any pre-existing data associated with the lead compounds.
Oligonucleotide therapeutics (oligos), a promising class of drugs that can modulate gene expression or protein function, are reshaping modern medicine. Finally, oligo metabolites often share similar structures and molecular weights with parent compounds, leading to potential interference during analysis.
The reality is that leading companies are looking for ways to drive impact that go beyond optimizing reach and frequency. To do this, they will not only need new knowledge but a substantially better ability to engage, connect and influence the HCP, leading to more meaningful interactions and increased conversion.
By starting collaborations early, relationships are initiated and involvement in the project happens during inception, leading to ownership and thereby maximising results. Neil obtained a degree in medicinal and pharmaceutical chemistry from Loughborough University.
Technological advancements, shifting market dynamics, and updated regulations are leading to significant changes within the pharmaceutical industry. The DOJ’s investigation revealed that the company misled HCPs and patients about the risks associated with the opioid, leading to overprescription and abuse.
Another game-changer has been the shift towards personalized medicine. This could mean staying updated with the latest industry trends, enrolling in advanced sales training programs, or pursuing further education in areas like business management or pharmacology. Embracing a mindset of lifelong learning keeps you agile and adaptable.
This could lead to significant research waste. 5 When these medicines are prescribed to patients, we can use feedback from the real-world data that documents clinical outcomes, efficacy measures, patient-reported outcomes, and adverse events. Expert Review of Clinical Pharmacology. British journal of pharmacology.
Cancer remains a global threat with around 10 million people dying from the disease each year worldwide, making it the second leading cause of death. 3 With greater scientific understanding of cancer, the industry has made significant progress in developing innovative medicines to help patients. 1,2 In the EU, an estimated 2.7
Over 100 biosimilar medicines are approved for nearly 30 reference medicines, testimony to the rigour of the scientific standards leading to the European authorisation process. These reconsiderations lead the way to liberating untapped potential from biological standards of care. 6 billion in 2024 alone).
You want to use it to show what is working well, or tell ‘if you’re struggling in this situation, I want to identify the trigger,’” says Dr. Jose Castillo-Mancilla, associate professor, School of Medicine, University of Colorado, Anschutz. But the pharmacology to quantify adherence also depends on race, gender, weight, and other factors.
This is due to aging populations around the world, which leads to an increased risk of such conditions, explains Craig Beavers, PhD, assistant professor at the University of Kentucky’s College of Pharmacy in Lexington. There needs to be more investment into local production to improve the availability of these medicines, says Page.
2 Approach taken by regulators in the UK The Medicines and Healthcare products Regulatory Agency regulates herbal medicines in the UK. Herbal medicines placed on the market since April 2011 must have either a traditional herbal registration (THR) or a Marketing Authorisation (MA). 2012/1916). 2012/1916). 2012/1916). 2012/1916).
Most drugs being developed now are more tailored to specific mechanisms of action compared to past drugs, says Dr. Gareth Veal, PhD, a professor of cancer pharmacology at Newcastle University. Ratain says achieving the right dosage requires an understanding of clinical pharmacology and a randomised trial.
Innovation in precision medicine and genomic profiling is shaping the future of cancer treatment. Hait: When leading R&D at Johnson & Johnson , the World Without Disease Accelerator revolutionized healthcare by focusing on disease prevention rather than merely treating diseases. Dr. William N.
Entering into select, high-value collaborations allows us to efficiently deploy our platform together with leading companies while we continue to build out our own pipeline of innovative and impactful medicines.”
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content